Kenvue Inc. (NYSE:KVUE) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG lifted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,693,952 shares of the company's stock after purchasing an additional 452,294 shares during the quarter. Deutsche Bank AG owned 0.56% of Kenvue worth $228,316,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of KVUE. Price T Rowe Associates Inc. MD raised its holdings in shares of Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares during the period. Vanguard Group Inc. raised its holdings in shares of Kenvue by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after acquiring an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after acquiring an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after acquiring an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. UBS Group increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Citigroup raised their price objective on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research report on Friday, May 9th. Finally, Canaccord Genuity Group lifted their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $25.33.

Kenvue Stock Performance

Shares of NYSE KVUE traded up $0.49 during mid-day trading on Thursday, hitting $23.69. The stock had a trading volume of 8,951,360 shares, compared to its average volume of 17,041,620. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a 50 day moving average of $23.15 and a two-hundred day moving average of $22.58. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17. The firm has a market cap of $45.44 billion, a PE ratio of 44.69, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company's revenue was down 3.9% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.46%. Kenvue's dividend payout ratio (DPR) is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.